MKI67 and chronic kidney disease: We found a strikingly decreased Ki-67 labeling index when Cinacalcet was administered early in the inactive phase at ZT2 (Cina1) as compared to when Cinacalcet was administered early in the active phase at ZT14 (Cina1 vs. Cina2: 0.92±0.14% vs. 2.46±0.37%, p = 0.006) and when compared to the untreated CKD groups at ZT2 (Cina1 vs. PNX1: 0.92±0.14% vs. 3.45±0.47%, p = 0.0002) and at ZT14 (Cina1 vs. PNX2: 0.92±0.14% vs. 4.15±0.47%, p = 0.0001), respectively.